Published in Oncoimmunology on October 15, 2013
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov (2014) 1.38
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med (2014) 0.95
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology (2014) 0.89
T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. Semin Immunopathol (2017) 0.85
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol (2015) 0.82
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology (2016) 0.81
High-content molecular profiling of T-cell therapy in oncology. Mol Ther Oncolytics (2016) 0.79
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep (2016) 0.77
The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget (2016) 0.77
Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol (2016) 0.77
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clin Cancer Res (2016) 0.75
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma. Neurology (2017) 0.75
First-line treatment of metastatic melanoma: role of nivolumab. Immunotargets Ther (2017) 0.75
The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. Onco Targets Ther (2016) 0.75
Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy. BMC Surg (2016) 0.75
Ligation-anchored PCR unveils immune repertoire of TCR-beta from whole blood. BMC Biotechnol (2015) 0.75
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med (2017) 0.75
Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. Ann Transl Med (2015) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
Disparate individual fates compose robust CD8+ T cell immunity. Science (2013) 2.80
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 2.15
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood (2013) 1.50
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Predicted complementarity determining regions of the T cell antigen receptor determine antigen specificity. EMBO J (1995) 0.92
Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area. Mol Immunol (1998) 0.90
Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol (2006) 0.89
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol (2006) 3.42
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 2.91
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med (2008) 2.81
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A (2007) 2.39
Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol (2004) 2.38
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol (2007) 2.34
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28